Lack of evidence for improved β-adrenoceptor-mediated papillary muscle contraction by low-dose empagliflozin treatment in a rat model of streptozotocin-induced diabetes
- 11 January 2026
- journal article
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 30 (1) , 60-71
Abstract
Diabetes mellitus leads to cardiovascular complications including impaired cardiac β-adrenoceptor (β-AR) function. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA), improve outcomes in heart failure patients and animal models. Therefore, we have investigated the effects of EMPA on in vivo cardiac function and β-AR mediated contractile responses in streptozotocin (STZ)-induced diabetes in a design reflecting late-onset of treatment. Male Sprague Dawley rats were divided into 4 groups (control, EMPA-treated control, diabetic, and EMPA- treated diabetic). Diabetes was induced by STZ injection (40 mg/kg). 13-16 weeks after STZ injection, a low dose of EMPA (10 mg/kg/day, daily oral gavage) or vehicle was administered for another 8 weeks. At the end of the treatment period, in vivo cardiac function was evaluated by pressure-volume (PV) loop analysis and β-AR mediated contractile response was determined by isoprenaline on isolated papillary strips. The blood glucose-lowering effect of low-dose EMPA was confirmed. EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate, cardiac output, stroke work, rate of contraction and rate of relaxation and increased isovolumic relaxation, whereas in vitro responses were not markedly attenuated. Treatment with EMPA showed a trend for improvement of some (e.g., stroke volume, ejection fraction, cardiac index) but not all parameters. Our results indicate that low-dose EMPA treatment had limited effects on cardiac impairment despite reducing blood glucose when initiated after diabetes has manifested. Future studies using a preventive rather than therapeutic approach could help to clarify the possible benefits of EMPA on the diabetic heart.Keywords
This publication has 67 references indexed in Scilit:
- Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fractionNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT/JAK/MAPK pathways in streptozotocin-induced diabetic ratsChemico-Biological Interactions, 2021
- ICS 2021 MELBOURNE ONLINE SCIENTIFIC PROGRAMMENeurourology and Urodynamics, 2021
- Choice of y-axis can mislead readersNaunyn-Schmiedeberg's Archives of Pharmacology, 2020
- IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045Diabetes Research and Clinical Practice, 2018
- A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin‐induced rat modelsNeurourology and Urodynamics, 2018
- Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 DiabetesCardiovascular Drugs and Therapy, 2017
- SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 InhibitorCardiovascular Drugs and Therapy, 2017
- A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humansNaunyn-Schmiedeberg's Archives of Pharmacology, 2015
- The role of insulin–thyroid hormone interaction on β-adrenoceptor-mediated cardiac responsesEuropean Journal of Pharmacology, 2013